There's a number in there that is telling. The NHS recommends mammography once every three years?!? Now come on, people! Surely you can intuit that the only possible reason for this is cost-savings.
We screen every year and have better survival and mortality rates. Further evidence that the NHS crafts their guidelines to save money at the expense of people's lives.
Just in case the message didn't get through:
Ooooooooooooh, look SCIENCE!!!!
A large research trial in 2002 concluded that the NHS Breast Screening Programme has got the interval between screening and invitations about right at three years, compared with more frequent screening. The trial was organised through the United Kingdom Coordinating Committee on Cancer Research (UKCCCR) and was supported by the Medical Research Council, Cancer Research UK and the Department of Health.
Here are the results from the UKCCCR Randomised Trial (PDF-186Kb) from the European Journal of Cancer, 2002.
http://www.cancerscreening.nhs.uk/breastscreen/EJC.38.11.pdf
The frequency of breast cancer screening: results from the
UKCCCR Randomised Trial
The Breast Screening Frequency Trial Group*,1
Received 23 October 2001; accepted 23 October 2001
Abstract
The optimal frequency of breast cancer screening has been a subject of debate since the inception of the UK National Breast
Screening Programme (NHSBSP). This paper reports on the only randomised trial directly comparing different screening intervals.
99 389 women aged 50–62 years who had been invited to a prevalent screen were randomly allocated after the scheduled prevalent
screen date to the study arm (invited to three further annual screens),or to the control arm (invited to the standard single screen 3
years later). 37 530 women in the study arm and 38 492 in the control arm had attended the prevalent screen. The endpoint was
predicted breast cancer deaths. The prediction was based on both the Nottingham Prognostic Index (NPI) and a similar method
derived from survival data from a series of tumours in the Swedish Two-County screening trial (2CS). Both indices were based on
the size,lymph node status and histological grade of the invasive tumours diagnosed in the two arms of the trial. The pathology of
the cases diagnosed was subject to review by two pathologists using standard criteria. The tumours diagnosed in the study arm were
significantly smaller than those diagnosed in the control arm (P=0.05). The relative risk of death from breast cancer for the annual
compared with the 3-yearly group was 0.95 (95% Confidence Interval (CI): 0.83–1.07, P=0.4) using the NPI and 0.89 (95% CI:
0.77–1.03, P=0.09) using the 2CS.
Shortening of the screening interval in this age group is predicted to have a relatively small effect
on breast cancer mortality. Improvements to the screening programme would be targeted more productively on areas other than the
screening interval,such as improving the screening quality.
# 2002 Published by Elsevier Science Ltd.
Keywords: Mammography; Breast screening; Screening interval